Your browser is no longer supported. Please, upgrade your browser.
GILD Gilead Sciences, Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
IndexS&P 500 P/E- EPS (ttm)-0.24 Insider Own0.41% Shs Outstand1.26B Perf Week-4.30%
Market Cap78.03B Forward P/E8.92 EPS next Y6.98 Insider Trans-0.79% Shs Float1.25B Perf Month-5.11%
Income-257.00M PEG- EPS next Q1.96 Inst Own81.40% Short Float1.30% Perf Quarter-16.52%
Sales22.17B P/S3.52 EPS this Y1.10% Inst Trans-1.20% Short Ratio1.85 Perf Half Y-14.55%
Book/sh14.36 P/B4.33 EPS next Y-0.30% ROA-0.40% Target Price78.92 Perf Year-1.66%
Cash/sh15.09 P/C4.13 EPS next 5Y0.24% ROE-1.20% 52W Range60.89 - 85.97 Perf YTD-4.20%
Dividend2.72 P/FCF15.08 EPS past 5Y-10.50% ROI9.50% 52W High-27.59% Beta0.56
Dividend %4.37% Quick Ratio2.20 Sales past 5Y-2.00% Gross Margin78.60% 52W Low2.23% ATR1.41
Employees11800 Current Ratio2.30 Sales Q/Q-9.50% Oper. Margin-4.30% RSI (14)30.30 Volatility1.86% 2.16%
OptionableYes Debt/Eq1.34 EPS Q/Q-280.70% Profit Margin-1.20% Rel Volume0.82 Prev Close62.25
ShortableYes LT Debt/Eq1.17 EarningsJul 30 AMC Payout- Avg Volume8.73M Price62.25
Recom2.50 SMA20-4.33% SMA50-9.12% SMA200-12.90% Volume7,136,452 Change0.00%
Sep-15-20Upgrade Maxim Group Hold → Buy $88
Jul-31-20Reiterated Wells Fargo Equal Weight $87 → $76
Jul-31-20Reiterated SunTrust Hold $73 → $74
Jul-31-20Reiterated RBC Capital Mkts Outperform $89 → $87
Jul-31-20Reiterated Piper Sandler Overweight $90 → $85
Jul-31-20Reiterated Morgan Stanley Equal-Weight $80 → $79
Jul-31-20Reiterated Credit Suisse Neutral $75 → $73
Jul-20-20Upgrade Credit Suisse Underperform → Neutral $64 → $75
Jun-03-20Upgrade SVB Leerink Mkt Perform → Outperform $85 → $94
May-26-20Upgrade SunTrust Sell → Hold $73
May-01-20Downgrade SunTrust Hold → Sell $70
May-01-20Downgrade Raymond James Outperform → Mkt Perform
May-01-20Downgrade JP Morgan Overweight → Neutral
Apr-27-20Downgrade UBS Buy → Neutral $77 → $80
Apr-20-20Downgrade Wells Fargo Overweight → Equal Weight $87
Apr-20-20Downgrade BMO Capital Markets Outperform → Market Perform $79
Apr-17-20Downgrade CFRA Hold → Sell
Mar-31-20Initiated Wolfe Research Peer Perform
Mar-20-20Upgrade Piper Sandler Neutral → Overweight $70 → $90
Mar-18-20Upgrade DZ Bank Hold → Buy $80
Sep-25-20 08:37PM  
01:00PM  
12:57PM  
09:30AM  
06:11AM  
02:00AM  
Sep-24-20 02:39AM  
12:05AM  
Sep-23-20 10:33PM  
10:11PM  
01:01PM  
09:45AM  
Sep-22-20 04:07PM  
12:09PM  
Sep-21-20 05:45PM  
01:42PM  
10:42AM  
08:05AM  
Sep-19-20 10:30AM  
Sep-18-20 05:23PM  
04:16PM  
12:11PM  
09:51AM  
07:42AM  
06:10AM  
Sep-17-20 09:00AM  
Sep-16-20 01:57PM  
09:47AM  
08:33AM  
06:05AM  
Sep-15-20 05:45PM  
02:35PM  
12:35PM  
12:09PM  
10:41AM  
10:05AM  
09:55AM  
08:18AM  
06:14AM  
02:31AM  
Sep-14-20 06:11PM  
04:38PM  
04:34PM  
04:31PM  
04:25PM  
04:23PM  
04:17PM  
04:15PM  
04:00PM  
04:00PM  
03:38PM  
03:22PM  
03:13PM  
02:45PM  
12:53PM  
12:48PM  
12:48PM  
12:20PM  
11:42AM  
11:27AM  
11:26AM  
11:19AM  
10:28AM  
10:22AM  
10:03AM  
10:03AM  
10:01AM  
09:45AM  
09:28AM  
09:00AM  
08:47AM  
07:51AM  
07:48AM  
07:30AM  
06:49AM  
03:02AM  
02:39AM  
01:27AM  
12:45AM  
Sep-13-20 10:41PM  
10:28PM  
08:11PM  
03:24PM  
03:14PM  
03:00PM  
01:56AM  
Sep-12-20 06:22PM  
03:49PM  
03:28PM  
06:53AM  
Sep-11-20 08:35AM  
Sep-09-20 05:45PM  
10:19AM  
09:13AM  
08:21AM  
05:21AM  
Sep-08-20 04:15PM  
01:58PM  
08:21AM  
Sep-07-20 10:22AM  
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections. In addition, the company offers its products under the name Cayston, Emtriva, Hepsera, Sovaldi, and Tybost. Further, it develops product candidates for the treatment of viral diseases, inflammatory and fibrotic diseases, and oncology. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Second Genome; Gadeta; Carna Biosciences Inc.; Nurix Therapeutics, Inc.; Humanigen, Inc.; Kiniksa Pharmaceuticals, Ltd.; Kyverna Therapeutics, Inc.; Glympse Bio, Inc.; Renown Institute for Health Innovation; Goldfinch Bio, Inc.; Insitro, Inc.; Novo Nordisk A/S; Yuhan Corporation; Kite Pharma, Inc.; oNKo-innate Pty. Ltd.; and Roche Holding AG. The company has partnership with Arcus Biosciences, Inc. to co-develop and co-commercialize next-generation cancer immunotherapies. Gilead Sciences, Inc. was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Parsey MerdadChief Medical OfficerAug 17Sale68.3218212,4340Aug 19 12:53 PM
Mercier JohannaChief Commercial OfficerJul 24Option Exercise0.007,50507,505Jul 28 06:47 PM
Rodriguez JavierDirectorJun 23Sale75.5018914,2700Jun 25 01:51 PM
Dickinson Andrew DEVP, Chief Financial OfficerJun 10Option Exercise0.003,646015,046Jun 12 03:28 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Option Exercise39.7613,210525,22527,854May 07 06:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMay 05Sale79.2313,2101,046,64014,644May 07 06:02 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Option Exercise66.3611,486762,21123,685May 06 06:40 PM
Cogan John FrancisDirectorMay 04Option Exercise19.632,41647,42657,276May 05 04:28 PM
Wilfong Diane E.SVP, Controller & CAOMay 04Sale80.0912,264982,22011,421May 06 06:40 PM
Cogan John FrancisDirectorMay 04Sale81.752,416197,50854,860May 05 04:28 PM
Cogan John FrancisDirectorApr 27Option Exercise19.632,41347,36757,273Apr 29 07:28 PM
Cogan John FrancisDirectorApr 27Sale79.902,413192,79954,860Apr 29 07:28 PM
Cogan John FrancisDirectorApr 20Option Exercise19.632,41347,36757,273Apr 21 07:42 PM
Cogan John FrancisDirectorApr 20Sale83.002,413200,27954,860Apr 21 07:42 PM
Cogan John FrancisDirectorApr 13Option Exercise19.632,41347,36757,273Apr 14 03:52 PM
Cogan John FrancisDirectorApr 13Sale75.902,413183,14754,860Apr 14 03:52 PM
Cogan John FrancisDirectorApr 06Option Exercise19.632,41347,36757,273Apr 07 05:34 PM
Cogan John FrancisDirectorApr 06Sale79.522,413191,88254,860Apr 07 05:34 PM
Cogan John FrancisDirectorMar 30Option Exercise19.632,41347,36757,273Mar 31 03:00 PM
Cogan John FrancisDirectorMar 30Sale75.352,413181,82054,860Mar 31 03:00 PM
Cogan John FrancisDirectorMar 23Option Exercise19.632,41347,36757,273Mar 24 08:42 PM
Cogan John FrancisDirectorMar 23Sale75.272,413181,62754,860Mar 24 08:42 PM
Cogan John FrancisDirectorMar 16Option Exercise19.632,41347,36757,273Mar 17 08:01 PM
Cogan John FrancisDirectorMar 16Sale67.262,413162,29854,860Mar 17 08:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Option Exercise24.302,95071,67017,594Mar 12 08:30 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 10Sale75.552,950222,87314,644Mar 12 08:30 PM
Cogan John FrancisDirectorMar 09Option Exercise19.632,41347,36757,273Mar 10 09:16 PM
Cogan John FrancisDirectorMar 09Sale77.972,413188,14254,860Mar 10 09:16 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselMar 02Sale70.8810,441740,01414,644Mar 03 07:40 PM
Lofton Kevin EDirectorFeb 24Option Exercise19.6321,720426,36486,579Feb 25 05:13 PM
WILSON GAYLE EDirectorFeb 10Option Exercise19.6321,720426,364148,502Feb 11 07:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Option Exercise24.302,95071,67027,640Feb 12 06:25 PM
WILSON GAYLE EDirectorFeb 10Sale67.7221,7201,470,878126,782Feb 11 07:02 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 10Sale69.322,950204,49424,690Feb 12 06:25 PM
WOLD OLSEN PERDirectorFeb 07Option Exercise20.6520,282418,722118,136Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 07Sale70.001,42699,82024,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 07Sale69.0020,2821,399,45897,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Option Exercise40.565,000202,80029,690Feb 10 07:00 PM
WOLD OLSEN PERDirectorFeb 06Option Exercise19.6321,720426,364119,574Feb 10 06:25 PM
WOLD OLSEN PERDirectorFeb 06Sale68.1221,7201,479,60597,854Feb 10 06:25 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselFeb 06Sale68.185,000340,90124,690Feb 10 07:00 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Option Exercise24.302,95071,67020,014Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselJan 03Sale64.632,950190,65917,064Jan 06 07:01 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Option Exercise24.305,900143,34122,964Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselDec 03Sale65.775,900388,04317,064Dec 04 07:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Option Exercise40.5615,000608,40032,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 25Sale66.8515,0001,002,80917,064Nov 26 02:14 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 19Sale64.9110,000649,06217,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Option Exercise24.3010,000242,95027,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 18Sale63.8510,000638,50017,064Nov 20 06:11 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 05Sale66.062,095138,40417,826Nov 07 08:04 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Option Exercise16.892,40040,53623,921Nov 05 08:21 PM
Pletcher Brett AEVP,Corp Affairs & Gen CounselNov 01Sale64.524,000258,09919,921Nov 05 08:21 PM
Pletcher Brett AEVP, Gen Counsel & Corp SecOct 28Sale63.315,677359,41221,521Oct 30 08:35 PM
Lofton Kevin EDirectorOct 01Option Exercise0.0021,527064,859Oct 03 09:03 PM